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Frail older people have an inherent risk of polypharmacy due to the need to treat multiple comorbidities, thus leading to various
negative effects on their health due to the adverse actions from the drugs. 'is issue was discussed from a person-centered
perspective, highlighting the category of frail older adults who are at a higher risk. Appropriate medication reconciliation in this
population with useful prescribing tools (Beers and START/STOPP criteria) to minimize polypharmacy and to provide alternative
prescriptive intervention could go alongside primary care to reduce the extent of frailty and polypharmacy. Reducing delayed
referrals and extended hospitalization with electronic health record systems and using the signs of frailty from the Electronic
Frailty Index (EFI) to predict polypharmacy for frail older persons are preventative approaches that proactively respond to frailty
associated with the risk of polypharmacy.
1. Background
Frailty is a progressive condition characterized by a decline
in cognitive, emotional, and physical ability resulting from
the accumulation of gradual health deterioration [1] that
leads to hospital admissions and multiple prescriptions
which have not resulted in the best outcome [2]. Medication
usage in older people increases with age due to associated
comorbid conditions and the need to better manage overall
outcomes [3]. Poor correspondence and communication
between several health care providers could lead to the error
of multiple prescriptions leading to polypharmacy, greater
risk for adverse drug events, cognitive and functional im-
pairment, falls, and adherence problems which can adversely
impact the health of older persons and lead to higher risk for
frailty [4, 5].
Frailty is associated with multiple health deficiencies [2],
which suggests the need for treatment with multiple med-
ications specific to the disease. Fortin et al. [6] suggested that
multimorbidity is present in about 98% of the older pop-
ulation. 'is concurs with the cumulative deficit model of
frailty that states that as people age, they acquire health
deficits which confer increasing health risk [7]. As many
diseases require treatment with medications, the increasing
risk of side effects from medication is associated with frailty
[8]; hence, older people who are frail are likely to suffer from
the hazards of polypharmacy.
Polypharmacy is a defined risk for frailty [9]. It is “the
use of multiple medications and/or the administration of
more medications than are clinically indicated, representing
unnecessary drug use” [9]. It is associated with the use of
inappropriate medications that are either contraindicated or
pose a high risk to older persons [9, 10]. 'e severity of
frailty leads to the increasing intake of multiple medications
which althoughmay be recommended in the disease-specific
guidelines, could be inappropriate for the older person when
person-centered care is taken into account [11].
'ere is currently no consensus as to the multiple
medication use that amounts to polypharmacy because of
the need to treat presenting multiple comorbidities con-
currently with combinations of drugs [12]. In estimating the
combination of drugs that amounts to polypharmacy, some
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have said it is taking between 2 and 9 medications and others
say it is the use of 5 or more medications and that hyper-
polypharmacy amounts to the use of ten or more medica-
tions concurrently on a daily basis [12, 13]. Another
definition deemed more appropriate is the use of medica-
tions not clinically indicated [10]. 'is definition details that
some medications are clinically not needed and defines the
term as the usage of redundant and unnecessary medication.
A person-centered approach to frailty focuses on
knowing the frail older person, their values, and relation-
ships, and seeing beyond their immediate needs has been
suggested to be a proactive response to frailty [11, 14].'is is
especially important in relation to the risk of polypharmacy,
as the addition of a new medication for older people with
frailty may trigger sudden changes in their mental and
physical health [11].
'is essay studies the associated risk of frailty using the
cumulative deficit model which identifies frailty as an ac-
cumulation of health deficiencies [7]. Frailty will be dis-
cussed in relation to the risk of using multiple medications
among frail older people from a person-centered perspec-
tive. It highlights the category of frail older persons more at
risk and explains how a Comprehensive Geriatric Assess-
ment (CGA) and a reduction in patient waiting time to
access health care reflect person-centered approaches. 'ree
preventative approaches, namely, efficient electronic med-
ical record system, useful prescription aids (Beers and
STOPP/START criteria), and social prescribing, will be
explored to understand frailty in the older person in relation
to the risk of polypharmacy, and optimization of functional
capacity.
2. Frailty in the Older Person in
relation to Polypharmacy
Current definitions of frailty place emphasis on the con-
dition as a vulnerability characterized by loss of physio-
logical reserves, emotional disorders, and inability to
withstand acute illness [15, 16].'e cumulative deficit model
by Rockwood [7] defines frailty as a situation where deficits
outweigh the assets (well-being and functional capacity),
while another definition by Fried is based mainly on five
phenotypic criteria of physical dysfunction which includes
low energy, low grip strength, slow walking speed, unin-
tentional weight loss, and low physical activity [17]. Rock-
wood [7] operationalized a frailty index of 70 items
characterized by many conditions (disability, cognitive and
physical impairments, geriatric conditions, and psychosocial
risks) that could lead to increased risk of developing adverse
drug reactions (ADRs) [18].'e physical manifesting factors
or deficits of frailty are more likely to be identified and
treated by clinicians than psychosocial factors, which raises
concerns on the overall awareness of the issue, and is further
complicated by the fact that a formal consensus on the
definition of frailty is lacking [19].
Frailty is complex in the manner it occurs, and there are
no general treatments. Medicinal interventions need to be
person centered to examine the situation from the per-
spective of the person with the condition [19]. Person-
centered care emphasizes the need for services to better
engage with and be responsive to individual needs [20].
Although in the literature similar terms such as “patient-led”
and “client-directed” have been used to refer to person-
centered care with different emphasis [20], a common
definition is that it prioritizes understanding the person’s
unique interpretation and experience of the illness [21] and
taking cognizance of the decision made by the frail person in
a positive care relationship [22, 23].
Frailty has been described as one of the factors which
make polypharmacy more likely, as it is difficult for frail
older persons with comorbid conditions to prevent the need
for new prescriptions in ongoing clinical management [16].
'e prevalence of polypharmacy is fueled by salient and
nonspecific symptoms at hospital admissions [24]; more-
over, the strong correlation between frailty and poly-
pharmacy among older individuals and the risk for
polypharmacy is high [25]. A descriptive cohort study to
assess frailty, total number of health problems requiring
treatment, geriatric problems, and medication among 250
patients aged above 65 years revealed that polypharmacy
among frail patients had more significant health problems,
longer hospital stays, and five times greater risk of read-
mission than patients without frailty and polypharmacy
[24]. Another longitudinal and 8-year follow-up study by
Veronese et al. [25] to investigate whether polypharmacy is
linked with a higher incidence of frailty in a large cohort of
4402 North Americans at high risk of, or having, knee
osteoarthritis, found that the incidence of frailty was sig-
nificant in those taking 4–6 medications and 6 times higher
in people taking 7 or more medications. 'ese evidence-
based studies suggest that taking more medications than are
clinically indicated does not translate to better health for
older people who are frail.
In addition, a study [13] involving 1705 community-
dwelling older men that sought to identify those at risk of
different adverse outcomes found that the use of 6.5 med-
ications daily was associated with the risk of frailty and that
the risk of being frail increases by 27% when the number of
medication increases by one. 'is increase in medication
leads to a 15% rise in the risk for falls and early mortality
[13]. 'us, this suggests that polypharmacy and the risk for
frailty are not only correlated but associated with other
geriatric conditions which overtime could predict severe
outcomes. 'e highlighted evidence establishes the rela-
tionship between the two and shows a rise in the risk for
being frail in polypharmacy and hyperpolypharmacy
compared with no polypharmacy.
It is important to prevent adverse events in order to create
an environment where frail patients could thrive [26]. Budnitz
et al. [27] reported that adverse drug reactions involved in
prescription medication were common in one-third of
emergency visits by older people. In 1996, Goldberg et al. [28]
also reported that patients who took two drugs at the same time
were found to have a 13% risk of adverse drug events, while
those who took four and seven or more medications con-
currently were 38% and 82% respectively at risk. 'e reports
reveal that the more drugs one consumes, the higher the risk of
adverse events due to a change in pharmacokinetics, drug-drug
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interaction, and drug interaction with living systems [29] and is
a concern for frail older people who combine multiple med-
ication concurrently [25, 30]. 'erefore, it could be counter-
productive to administer a large number of medications for
multimorbid geriatric conditions without a comprehensive
assessment.'e comprehensive geriatric assessment (CGA) is a
person-centered approach that could be used to reduce the
extent of frailty associated with the risk of polypharmacy be-
cause it concentrates on medication that produces benefit but
avoids those most likely to cause harm [19]. It is a holistic
medical review involving multidimensional assessment and
dialogue with older frail persons to understand their difficulties
with activities of daily living and to create a comprehensive
road map for care using evidence-based aids such as Beers
criteria and STOPP/START criteria to improve prescribing
[11, 31]. 'e comprehensive assessment optimize care by
providing an alternative to medication when it is not vital and
giving the patients the chance to prioritize care most appro-
priate for them.
'e extent of frailty is associated with increasing number
of health deficits that leads to frequent hospitalization and
nursing home admission of older patients, increasing the
risk for polypharmacy [32]. Nursing home residents are said
to have the highest rate of polypharmacy because of the
potential for increased diagnoses that correlates with in-
creased health deficiency [33]. About 60% of home resi-
dential older persons (>75 year) in Denmark use more than
3 medications [34]. In Italy, 52% of hospitalized older pa-
tients take an average of 4.9 medications; in the United
States, about 50% of hospitalized older patients take at least
7, while in Austria, 58% consume an average of 7.5 medi-
cations [32, 35, 36].'e distribution shows a high percentage
of multiple drug use among hospitalized older persons
compared with independent living residents.
Frail olderpeople feel insecure when they do not have the
opportunity to contact a physician to communicate suspected
worsening conditions [37]. It is important to note that effective
patient communication [26] and a reduction in patient waiting
time to access health care are person-centered approaches that
enable frail older persons to have access to health care [38].
Short periods of consultation with a physician due to shortage
of practitioners would likely not allow for a holisticmedication
review and comprehensive geriatric assessment (CGA) [39].
More health providers are needed to reduce patient waiting
time and to routinely review older adult medication to prevent
avoidable polypharmacy [40].
Consequently, it could be suggested that polypharmacy
increases with advancing age [10] due to accumulation of
deficits. Global estimation has it that 44.2–57.7% of adults
aged 65 years or more are on at least 5 different drugs and
9.1–23.2% on 10 or more different drugs [30, 41]. 'ere is no
consensus on the increasing risk of polypharmacy among
adults in their fourth age (≥85 years) while Jyrkkan et al. [42]
and Haider et al. [43, 44] found that being in the oldest old
category is a high risk factor, Onder et al. [45], Kim et al.
[46], and Anja et al. [41] associated it with a lower risk of
polypharmacy. Targeting factors that reduces the extent of
frailty will lead to a reduction in polypharmacy and the
accumulated deficits [47].
3. Preventative Approaches
An important objective of person-centered care for frail
older people is to proactively respond to frailty to reduce the
occurrence of polypharmacy [11]. To achieve this, the
choices of older adults will have to be respected with more
consideration of them as partners in their own health care
[14]. Recommended preventative approaches include an
efficient electronic medical record system, useful aids for
appropriate prescription writing, social prescribing, and
optimizing functional capacity by intravenous delivery of
human allogenic mesenchymal stem cells.
A detailed electronic medical record would facilitate
regular comprehensive review of older patient’s prescrip-
tions from healthcare providers and allow the patients to be
more engaged in their own care [26]. Many physicians have
little information about the patient’s previous medical
history and may prescribe without prior knowledge of what
other physicians had recommended [48, 49]. An accessible
electronic medical database would assist physicians in
prescribing new drugs, reviewing medication efficacy, and to
discontinue certain medications when alternatives with
lesser adverse events exist [29]. 'is person-centered
management program could be a way that proactively re-
sponds to frailty [26], to prevent avoidable polypharmacy
and high risk for adverse drug events arising from multiple
physicians’ prescription [48].
Additionally, the electronic medical record allows access
to an Electronic Frailty Index (EFI) which is used to find out
and foretell adverse events for frail older patients [50]. It
consists of 36 signs of frailty and a range of values that can be
used to detect no frailty and mild-to-severe frail conditions.
For example, older people with 12 signs of frailty would be
classified as having the intermediate form [50]. Signs of
frailty from the Electronic Frailty Index could be used to
predict polypharmacy and adverse drug effects. Another
advantage of the electronic medical record system is that it
could prevent older people from being subjected to extended
hospitalization and delayed referrals due to a complex
medical history, as a reduction in time spent in hospital care
reduces further frailty complexity and drug intake [32]. 'e
advantages of EHR can be maximized if physicians can easily
use it within a short period of time. Habboush et al. [51]
reported that physicians spend about 49% of their working
hours on indirect patient-related tasks such as EHR docu-
mentation and chart review. Development of more user-
friendly EHRs and proper medical education for physicians
on its usage could translate into more physician time with
patients [51].
Another strategy that could mitigate worsening frail
conditions and halt adverse drug events is social prescribing.
Social prescribing is a way of referring patients to com-
munity groups and services for practical and emotional
support [52]. It expands the options available to healthcare
providers and gives patients the opportunity to form new
relationships and take part in their own self-management
[53, 54]. Since it has been reported that 8 or more diagnoses
increases the risk of polypharmacy [41], social prescribing
could go alongside with primary care to reduce
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polypharmacy [55], by connecting frail older people in
healthcare services to community support providing a range
of unorthodox prescriptive interventions such as volun-
teering, participating actively with exercise, and perfor-
mance groups to foster social connectedness [52, 55–58]. An
international consensus report on frailty in 2013 supports
the fact that frailty could be treated to reduce polypharmacy
by promoting physical activity with regular exercises, to
optimize the functioning of the oldest old [59].
In a randomized and double-blind study by Tompkins
et al. [60], results suggested that intravenous delivery of
human allogenic mesenchymal stem cells in frail older
people for bone and tissue repair, better physical perfor-
mance, and resistance to inflammation is a possible way of
reducing accumulated health deficits to optimize the
functioning of the oldest old. 'e study which involved 30
older adults—10 in each of the three groups (two treatment
and one control)—revealed a decrease in inflammatory
markers (e.g., TNF-α) in the treatment group [60] and is
consistent with similar findings by Schulman et al. [61]. A
drawback of this study is that more reliable evidence is
needed because of the small sample size and the lack of
clarity on its application. However, the findings provide
evidence that the extent of frailty and polypharmacy could
be reduced by a reduction in the deficits and intake of more
drugs (e.g., anti-inflammatory drugs) [62].
Furthermore, inappropriate prescribing is a concern for
older people who are frail because they have altered phar-
macokinetics that decreases the liver and kidney function as
a result of reduced hepatic and renal clearance and altered
pharmacodynamics that increases sensitivity to several drugs
[2, 63]. 'is is more worrying as about 50% of older persons
take drugs that are not necessary [33, 64]. Improved
medication prescription using aids such as Beers criteria and
the STOPP/START criteria can prevent unnecessary med-
ication usage from a person-centered perspective by taking
the contraindications and comorbidities of the frail indi-
vidual into account [11].
'e American Geriatrics Society (AGS) 2015 Beers
criteria is a prescription aid focusing on drug monitoring to
help frail older persons and healthcare providers, especially
physicians, to choose a better combination of prescription
medications, assess health outcomes among older patients,
and evaluate the proper use of the selected drugs [65]. 'e
screening tool of older people’s prescriptions (STOPP) and
the screening tool to alert right treatment (START) is an-
other widely used prescription aid [66] that aims to avoid
omissions and inappropriateness in prescription and has
been reported to reduce the risk of adverse drug effect by
9.3% within three days of hospital admission [64]. 'e
STOPP criteria for frail older persons (>65 years) is largely
associated with adverse drug events and recommend against
taking medications to treat symptoms unassociated with
selected illnesses; however, the START criteria allows
medication to be taken only when there is a documented
history of the indicated illness and when more suitable drugs
are contraindicated [67].
In essence, the prescription aids are part of the com-
prehensive geriatric assessment that takes the cumulative
health deficit of the frail person into account and prescribes
medication by understanding their history and lifestyle from
a person-centered perspective [19, 26]. Using these bench-
marks, healthcare providers can routinely review prescrip-
tion drugs for older patients with multiple diagnoses and
ensure prescribed drugs are clinically safe and more effec-
tively reduce the risk of adverse events [26].
4. Conclusion
Frailty results from the accumulation of multiple age-re-
lated health deficiencies that require drug therapies.
Causality exists between frailty and polypharmacy, and the
risk for polypharmacy among frail older persons is high
because of the need to treat multiple age-related disease
conditions. 'e intake of multiple combinations of drugs
increases the chance of accumulating health deficits arising
from the side effects of drugs, resulting in poor health
outcomes and increased risk of developing adverse drug
reactions (ADRs).
A reduction in accumulated health deficiencies using
person-centered approaches that better engages with frail
individuals has been suggested as a forward-looking re-
sponse to frailty. Allowing frail patients to effectively
communicate with healthcare providers by reducing the
waiting time to access health care and providing a com-
prehensive road map for care through a comprehensive
geriatric assessment are person-centered approaches that
could reduce the extent of frailty and polypharmacy.
In addition, carefully reviewing medication regimens to
provide alternative prescriptive interventions such as ex-
ercise and social participation could go alongside primary
care in optimizing the functional capacity of frail older
people using intravenous delivery of human allogenic
mesenchymal stem cells. 'ese preventative approaches
could reduce the extent of frailty and polypharmacy.'e use
of electronic health records to provide a comprehensive
evaluation of health status may lower the rate of delayed
referrals and shorten hospital stays, which reduces further
frailty complexity. Signs of frailty from the Electronic Frailty
Index (EFI) can be used to predict polypharmacy for frail
older persons, while useful prescribing tools (Beers and
START/STOPP criteria) can serve to enhance the physi-
cian’s medical judgment and are invaluable tools to mini-
mize the risk of polypharmacy.
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